8-K: Carisma Therapeutics Achieves Milestone with Moderna Collaboration, Receives $2 Million Payment

Carisma Therapeutics has announced the nomination of its first development candidate under its collaboration with Moderna, triggering a $2 million milestone payment.

Summary

• Carisma Therapeutics has announced that Moderna has nominated the first development candidate under their collaboration agreement.
• The development candidate is an in vivo chimeric antigen receptor macrophage (CAR-M) therapy targeting Glypican-3 (GPC3).
• This therapy is designed to treat solid tumors, including hepatocellular carcinoma, a prevalent form of liver cancer.
• The nomination of this candidate triggers a $2 million milestone payment to Carisma.
• The collaboration combines Carisma's expertise in CAR-M technology with Moderna's mRNA and lipid nanoparticle platform.
• Pre-clinical data suggests the therapy can create CAR-M directly in vivo, redirecting immune cells to attack cancer cells.
• Moderna has also nominated four other undisclosed oncology research targets under the collaboration.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the achievement of a significant milestone, the $2 million payment, and the potential of the in vivo CAR-M therapy. The collaboration with Moderna also adds to the positive outlook.

Positives

• The nomination of the first development candidate validates the collaboration between Carisma and Moderna.
• The $2 million milestone payment provides Carisma with additional funding.
• The in vivo CAR-M therapy has shown promising pre-clinical results.
• The therapy targets a significant unmet need in cancer treatment, specifically hepatocellular carcinoma.
• The collaboration leverages the strengths of both companies, combining Carisma's CAR-M expertise with Moderna's mRNA platform.

Risks

• The success of the therapy is dependent on positive results in future clinical trials.
• There are risks associated with the development and regulatory approval of new therapies.
• The company's ability to obtain additional capital is a risk factor.
• There are risks associated with the company's ability to manage expenses.
• The company's ability to protect its intellectual property is a risk factor.

Future Outlook

The companies anticipate further development of the nominated candidate for patients with solid tumors and continued success in developing additional in vivo CAR-M therapies. Carisma is responsible for the discovery and optimization of development candidates, while Moderna will lead the development and commercialization of resulting therapeutics.

Management Comments

• Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma, stated that the nomination underscores the productive collaboration with Moderna.
• Lin Guey, Chief Scientific Officer of Therapeutics Research Ventures and Biotherapeutics at Moderna, expressed excitement about the progress in advancing in vivo CAR-M therapies.

Industry Context

This announcement highlights the growing interest in cell-based immunotherapies for cancer treatment. The collaboration between Carisma and Moderna leverages the strengths of both companies in the development of novel cancer therapies. The focus on in vivo CAR-M therapy represents an innovative approach in the field.

Comparison to Industry Standards

• The development of in vivo CAR-M therapy is a relatively new approach compared to traditional CAR-T cell therapies, which require ex vivo cell manipulation.
• Companies like Kite Pharma and Novartis have pioneered CAR-T therapies, but in vivo approaches like Carisma's are gaining traction.
• The collaboration with Moderna, a leader in mRNA technology, positions Carisma to potentially develop a more efficient and scalable cell therapy.
• The focus on Glypican-3 as a target is relevant as it is highly expressed in hepatocellular carcinoma, a significant unmet medical need.

Stakeholder Impact

• Shareholders will likely view the milestone achievement and collaboration positively.
• Employees may be motivated by the progress in the company's research and development efforts.
• Patients with solid tumors, particularly hepatocellular carcinoma, may benefit from the development of this therapy.
• The collaboration with Moderna could enhance the company's reputation and attract further investment.

Next Steps

• Further development of the nominated candidate for patients with solid tumors.
• Continued development of additional in vivo CAR-M therapies.
• Carisma will focus on discovery and optimization of development candidates.
• Moderna will lead the development and commercialization of resulting therapeutics.

Key Dates

Keywords

CAR-M, immunotherapy, Moderna, Carisma Therapeutics, Glypican-3, Hepatocellular Carcinoma, Oncology, Cell Therapy, Milestone Payment, In Vivo